[{"orgOrder":0,"company":"Aguettant","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aguettant","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Sublingual Tablet","sponsorNew":"Aguettant \/ Laboratoire Aguettant","highestDevelopmentStatusID":"12","companyTruncated":"Aguettant \/ Laboratoire Aguettant"}]

Find Clinical Drug Pipeline Developments & Deals by Aguettant

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Under the DZUVEO licensing agreement, Aguettant will have the right to commercialize DZUVEO in Europe. In 2018, AcelRx received approval for DZUVEO from the European Commission for use in medically monitored settings.

Brand Name : Dzuveo

Molecule Type : Small molecule

Upfront Cash : Undisclosed

July 14, 2021

Lead Product(s) : Sufentanil Citrate

Therapeutic Area : Neurology

Highest Development Status : Approved

Recipient : AcelRx Pharmaceuticals

Deal Size : $55.0 million

Deal Type : Licensing Agreement

blank